Discriminatory Accuracy of Preeclampsia Risk Factors in Primary Care

Cordero-Franco, Hid Felizardo; Salinas-Martı́nez, Ana Marı́a; García-Alvarez, Tania Abigail; Maldonado-Sánchez, Eloísa Verónica; Garza, Francisco Javier Guzmán-de la; Mathiew‐Quirós, Álvaro

doi:10.1016/j.arcmed.2018.09.006

Cited by 6 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mean ± SD MAP was 93. 28 There were no statistically significant differences in the incidence of preeclampsia, baseline characteristics, or medications between the development and validation sets, except for mucocutaneous manifestation and aspirin use, but all these factors showed the same trends in the preeclampsia and nonpreeclampsia groups (see Supplementary Risk factors for preeclampsia among pregnant patients with SLE. Each variable with statistical significance (P < 0.05) in the univariate analysis of the development set was chosen as a potential predictor for preeclampsia (see Supplementary Table 2, available on the Arthritis Care & Research website at http://onlin elibr ary.wiley.com/doi/10.1002/acr.24265/ abstract).…”

Section: Discussionmentioning

confidence: 89%

“…MAP measurement in the first trimester has been shown to be effective in many predictive studies on preeclampsia, whether alone or in combination with ultrasound or biomarkers (15,(28)(29)(30)(31)(32)(33). In a retrospective analysis of the general population, a MAP ≥88 mm Hg predicted preeclampsia with a sensitivity of 0.78 and a specificity of 0.63, without previous medical history considered (30).The detection rate of preeclampsia using MAP increased from 43% to 67% when MAP was added to the maternal characteristics (34).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Preeclampsia Risk Prediction Model for Chinese Pregnant Patients With Systemic Lupus Erythematosus

Jiang

Wang

et al. 2020

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. To screen for a high risk of preeclampsia in women with systemic lupus erythematosus (SLE). Methods. A total of 513 antenatal care records of pregnant patients with SLE were obtained, and the data were randomly assigned to either a development set (n = 342) or a validation set (n = 171). Preeclampsia predictors were identified with stepwise regression, and a coefficient B of each variable was used to establish a prediction model and risk scoring system. Goodness-of-fit was assessed by the Hosmer-Lemeshow and Omnibus tests, and the area under the receiver operating characteristic curve (area under the curve) was used to assess discrimination. Validation was performed using the validation set. Results. The preeclampsia incidence was 14.4% in the pregnant patients with SLE. A mean arterial pressure (MAP) ≥96.5 mm Hg (odds ratio [OR] 213.15 [95% confidence interval (95% CI) 24.39-999.99]), prepregnancy hypertension (OR 18.19 [95% CI 2.67-125.01]), a hematologic disorder (OR 4.13 [95% CI 1.03-16.67]), positive IgM anticardiolipin antibodies (aCLs) (OR 19.85 [95% CI 1.11-333.33]), serum albumin <31.5 grams/liter (OR 9.88 [95% CI 2.07-47.62]), serum uric acid ≥303 μmoles/liter (OR 5.58 [95% CI 1.40-22.22]), and 24-hour urinary protein ≥0.286 grams (OR 14.39 [95% CI 2.43-83.33]) were selected for the preeclampsia prediction model. The area under the curve was 0.975. Preeclampsia prediction model scores >4 indicated a high risk of preeclampsia. For the validation set, the preeclampsia prediction accuracy was 93.6% (sensitivity 88.5%, specificity 94.5%). Conclusion. A model for predicting the risk of preeclampsia in pregnant patients with SLE was established on the basis of MAP, prepregnancy hypertension, hematologic disorders, IgM aCLs, albumin, uric acid, and 24-hour urinary protein. The model had good predictive efficiency and can help clinicians improve pregnancy outcomes in high-risk women with early interventions.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Preeclampsia Risk Prediction Model for Chinese Pregnant Patients With Systemic Lupus Erythematosus

Jiang

Wang

et al. 2020

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

“…Estimates of such diagnostic indicators were made using the free statistical package Epidat 3.1 23 . Diagnostic efficacy indicators were considered unacceptable, acceptable, or ideal based on the following criteria [24][25][26][27] : Sn, PPV, and NPV, ideal ≥ 80%, acceptable 60% to 79.9%, and unacceptable < 60%; Sp, ideal ≥ 95%, acceptable 90% to 94.9%, and unacceptable < 90%; LR+, ideal ≥ 10, acceptable 5 to10, and unacceptable < 5; and AUROC, ideal > 0.90, acceptable 0.70 to 0.90, and unacceptable < 0.70.…”

Section: Discussionmentioning

confidence: 99%

Procalcitonin and C-reactive protein: markers in the early diagnosis of anastomotic leak

Maldonado-Hernández,

Vega-Chavarría,

Nacud-Bezies

et al. 2024

CIRUE

View full text Add to dashboard Cite

Objective: To determine the efficacy of serum procalcitonin (PCT) and C-reactive protein (CRP) in the early diagnosis of anastomotic leak (AL) in patients undergoing colorectal surgery. Method: Diagnostic test in a tertiary care hospital. Patients who did not have preoperative measurements of PCT and CRP were excluded. Those with postoperative infection not related to AL were eliminated. The diagnostic efficacy measures were sensitivity (Sn), specificity (Sp), positive (PPV) and negative (NPV) predictive values, positive (LR+) and negative (LR−) likelihood ratios, and area under the receiver operating characteristic curve (AUROC). Results: Thirty-nine patients were analyzed; six had AL (15.4%). PCT and CRP increased on the second postoperative day, only in patients with AL. The cut-off points at the second postoperative day were 1.55 ng/mL for PCT and 11.25 mg/L for CRP.

show abstract

“…Las estimaciones de dichos indicadores se realizaron con el paquete estadístico gratuito Epidat 3.1 23 . Los indicadores de eficacia diagnóstica se consideraron inaceptables, aceptables o ideales, de acuerdo con los siguientes criterios [24][25][26][27] : S, VPP y VPN, ideales ≥ 80%, aceptable 60-79.9% e inaceptable < 60%; E, ideal ≥ 95%, aceptable 90-94.9% e inaceptable < 90%; RV+, ideal ≥ 10, aceptable 5-10 e inaceptable < 5; y AUROC, ideal > 0.90, aceptable 0.70-0.90 e inaceptable < 0.70.…”

Section: Análisis Estadísticounclassified

Procalcitonina y proteína C reactiva: marcadores en el diagnóstico temprano de fuga anastomótica

Maldonado-Hernández,

Vega-Chavarría,

Nacud-Bezies

et al. 2023

CIRU

View full text Add to dashboard Cite

Objetivo: Determinar la eficacia de la procalcitonina (PCT) y la proteína C reactiva (PCR) séricas en el diagnóstico de fuga anastomótica (FA) en los pacientes sometidos a cirugía colorrectal. Método: Prueba diagnóstica en un hospital de tercer nivel. Se excluyeron los pacientes que no tuvieron mediciones preoperatorias de PCT y PCR. Se eliminaron los que cursaron con infección posoperatoria no relacionada con FA. Las medidas de eficacia diagnóstica fueron sensibilidad (S), especificidad (E), valores predictivos positivo (VPP) y negativo (VPN), razones de verosimilitud positiva (RV+) y negativa (RV−), y área bajo la curva característica operativa del receptor (AUROC). Resultados: Se analizaron 39 pacientes, de los cuales 6 (15.4%) tuvieron FA. La PCT y la PCR aumentaron al segundo día posoperatorio solo en los pacientes con FA. Los puntos de corte al día 2 fueron 1.55 ng/ml para PCT y 11.25 mg/l para PCR.

show abstract

Discriminatory Accuracy of Preeclampsia Risk Factors in Primary Care

Cited by 6 publications

References 28 publications

Preeclampsia Risk Prediction Model for Chinese Pregnant Patients With Systemic Lupus Erythematosus

Preeclampsia Risk Prediction Model for Chinese Pregnant Patients With Systemic Lupus Erythematosus

Procalcitonin and C-reactive protein: markers in the early diagnosis of anastomotic leak

Procalcitonina y proteína C reactiva: marcadores en el diagnóstico temprano de fuga anastomótica

Contact Info

Product

Resources

About